Upcoming Medical Policies
BlueCross BlueShield of Tennessee

Each medical policy listed below will become effective on the date indicated, and will be included in the Medical Policy Manual for BlueCross BlueShield of Tennessee on that effective date.

Medical policies are developed using an evidence-based evaluation process.  The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and opinions from appropriate network specialists. All Medical Policies are reviewed by a panel of internal and external physicians before being adopted by the company.

Topics due to be included in the Medical Policy Manual on 1/10/2015

Topics due to be included in the Medical Policy Manual on 2/8/2015

Topics due to be included in the Medical Policy Manual on 2/18/2015

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Topics due to be included in the Medical Policy Manual on 1/10/2015:

Autologous Fat Grafting to the Breast and Adipose-Derived Stem Cells

Genetic Testing for Mitochondrial Disorders

Serum Biomarker Tests for Multiple Sclerosis (MS)

Transcranial Magnetic Stimulation, Cranial Electrotherapy Stimulation and Navigated Transcranial Magnetic Stimulation)

Topics due to be included in the Medical Policy Manual on 2/8/2015:

Chromosomal Microarray Testing for Evaluation of Early Pregnancy Loss

Complementary and Alternative Medicine

Topics due to be included in the Medical Policy Manual on 2/18/2015:

Bevacizumab for the Treatment of Neoplastic Disease

Pralatrexate


Last Review Date: 12/16/2014

 

Medical Policy Comments:

Please reference the policy name or tracking number in your comments.
To submit comments about the upcoming Medical Policies:
Click the “Medical Policy Comments” above or click here: Comments or Feedback.

Comments can also be mailed to:

BlueCross BlueShield of Tennessee
Medical Policy
1 Cameron Hill Circle
Chattanooga, TN 37402